Ethan D Borre, Mohamed M Diab, Austin Ayer, Gloria Zhang, Susan D Emmett, Debara L Tucci, Blake S Wilson, Kamaria Kaalund, Osondu Ogbuoji, Gillian D Sanders
BACKGROUND: Hearing loss is a common and costly medical condition. This systematic review sought to identify evidence gaps in published model-based economic analyses addressing hearing loss to inform model development for an ongoing Lancet Commission.
METHODS: We searched the published literature through 14 June 2020 and our inclusion criteria included decision model-based cost-effectiveness analyses that addressed diagnosis, treatment, or prevention of hearing loss. Two investigators screened articles for inclusion at the title, abstract, and full-text levels. Data were abstracted and the studies were assessed for the qualities of model structure, data assumptions, and reporting using a previously published quality scale.
FINDINGS: Of 1437 articles identified by our search, 117 unique studies met the inclusion criteria. Most of these model-based analyses were set in high-income countries ( = 96, 82%). The evaluated interventions were hearing screening ( = 35, 30%), cochlear implantation ( = 34, 29%), hearing aid use ( = 28, 24%), vaccination ( = 22, 19%), and other interventions ( = 29, 25%); some studies included multiple interventions. Eighty-six studies reported the main outcome in quality-adjusted or disability-adjusted life-years, 24 of which derived their own utility values. The majority of the studies used decision tree ( = 72, 62%) or Markov ( = 41, 35%) models. Forty-one studies (35%) incorporated indirect economic effects. The median quality rating was 92/100 (IQR:72-100).
INTERPRETATION: The review identified a large body of literature exploring the economic efficiency of hearing healthcare interventions. However, gaps in evidence remain in evaluation of hearing healthcare in low- and middle-income countries, as well as in investigating interventions across the lifespan. Additionally, considerable uncertainty remains around productivity benefits of hearing healthcare interventions as well as utility values for hearing-assisted health states. Future economic evaluations could address these limitations.
FUNDING: NCATS 3UL1-TR002553-03S3.
